HomeCompareKNCRY vs PFE

KNCRY vs PFE: Dividend Comparison 2026

KNCRY yields 2.26% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $5.5K in total portfolio value· pulled ahead in Year 10
10 years
KNCRY
KNCRY
● Live price
2.26%
Share price
$8.43
Annual div
$0.19
5Y div CAGR
31.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.1K
Annual income
$6,820.22
Full KNCRY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — KNCRY vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKNCRYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KNCRY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KNCRY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KNCRY
Annual income on $10K today (after 15% tax)
$192.17/yr
After 10yr DRIP, annual income (after tax)
$5,797.19/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $16,522.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KNCRY + PFE for your $10,000?

KNCRY: 50%PFE: 50%
100% PFE50/50100% KNCRY
Portfolio after 10yr
$46.8K
Annual income
$16,539.47/yr
Blended yield
35.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

KNCRY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.4
Piotroski
8/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KNCRY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKNCRYPFE
Forward yield2.26%6.13%
Annual dividend / share$0.19$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR31.9%13.2%
Portfolio after 10y$44.1K$49.6K
Annual income after 10y$6,820.22$26,258.71
Total dividends collected$21.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: KNCRY vs PFE ($10,000, DRIP)

YearKNCRY PortfolioKNCRY Income/yrPFE PortfolioPFE Income/yrGap
1$10,998$298.20$9,153$693.39+$1.8KKNCRY
2$12,172$404.29$8,593$849.25+$3.6KKNCRY
3$13,576$551.58$8,336$1,066.78+$5.2KKNCRY
4$15,285$758.35$8,437$1,384.80+$6.8KKNCRY
5$17,407$1,052.48$9,013$1,875.40+$8.4KKNCRY
6$20,103$1,477.56$10,306$2,680.72+$9.8KKNCRY
7$23,614$2,103.51$12,820$4,101.38+$10.8KKNCRY
8$28,313$3,045.86$17,673$6,826.70+$10.6KKNCRY
9$34,796$4,501.78$27,543$12,591.86+$7.3KKNCRY
10← crossover$44,052$6,820.22$49,560$26,258.71$5.5KPFE

KNCRY vs PFE: Complete Analysis 2026

KNCRYStock

Konecranes Plc manufactures, sells, and services cranes, lifting equipment, and machine tools worldwide. It operates through three segments: Service, Industrial Equipment, and Port Solutions. The company offers specialized maintenance services and spare parts for industrial cranes and hoists. It also provides a range of industrial cranes for general manufacturing and various process industries; and crane components and lifting equipment solutions to other crane manufacturers and distributors. In addition, the company offers container handling equipment and mobile harbor cranes, as well as port solution related software. Further, its products include workstation lifting systems, overhead cranes, hazardous environment cranes and hoists, lift trucks, and bulk handling equipment, as well as cores for lifting; and services comprise maintenance, inspection and preventive maintenance, predictive maintenance and remote monitoring, corrective maintenance and retrofit, consultation, modernization, and remote services. The company serves the automotive, container handling, mining, general manufacturing, nuclear, petroleum and gas, power, paper and forest, shipyard, metals production, and waste to energy and biomass industries. Konecranes Plc was founded in 1910 and is headquartered in Hyvinkää, Finland.

Full KNCRY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this KNCRY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KNCRY vs SCHDKNCRY vs JEPIKNCRY vs OKNCRY vs KOKNCRY vs MAINKNCRY vs JNJKNCRY vs MRKKNCRY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.